Table 3 Feasibility trial quantitative secondary outcomes and process measures
Outcome | Process measure |
|---|---|
Length of hospital stay Days of therapy (and intravenous therapy) Diagnostics Number of antibiotics prescribed Number of antibiotic courses Repeat courses for same indication Number of courses for same indication Switches - Of frequency - Of dose - From intravenous to oral - From oral to intravenous - To alternative antimicrobial - From narrow to broad spectrum Discontinuation of therapy Number of courses concordant with local guidelines for antibiotic choice/duration Resistance rates Susceptibility Acquisition of multi-drug resistant organism Healthcare-associated infection Episodes of Clostridium difficile infection (CDI) methicillin-resistant Staphylococcus aureus (MRSA) gram-negative bacilli (GNB) | Clinical decision support (CDS) - CDS ‘work around’ - CDS alert frequency - CDS alert override - Use of CDS order set Time - To administration - To active therapy (first dose) - Spent prescribing Documentation of - Indication - Duration - Stop/review - Decision-making Switches from - Reserve to watch group antibiotic - Watch to access group antibiotic Adherence to clinical guidelines Adherence to documented sensitivity Appropriate dose for indication |